ArticleCureus2025
Adrenocortical Carcinoma and Inferior Vena Cava Thrombosis: Diagnosis and Perioperative Management.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenocortical carcinoma (ACC) is an endocrine malignancy with a poor prognosis due to its advanced stage at diagnosis and early metastatic potential. Misclassification is common when tumors arise near the renal-adrenal interface, particularly in cases with vascular invasion. We describe the case of a patient with a large retroperitoneal mass extending into the inferior vena cava whose initial imaging suggested a renal origin, resulting in deferred hormonal evaluation. Postoperative pathology confirmed ACC, and subsequent endocrine testing was consistent with a nonfunctional tumor. This case reinforces the need for improved guidelines and increased education, accounting for the variable presentations of ACC, to enhance diagnostic accuracy and optimize pre- and perioperative planning. As such, in cases of patients presenting with masses in the adrenal-adjacent regions, an endocrine workup of cortisol, androgens/estrogens, and mineralocorticoids should be the standard of care to rule out aggressive tumors such as ACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.